anemia – Page 2 – AJKD Blog

Anemia in Patients Approaching Dialysis: Moving From When to TREAT to Whether to TREAT

February 26, 2019 // 0 Comments

In late 2009, the primary results of the placebo-controlled Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) were published. TREAT randomized 4,038 patients [...]

HIF Away: Roxadustat Has Arrived!

August 2, 2016 // 0 Comments

Anemia management in patients with end-stage renal disease (ESRD) has always been a complicated process. Prior to the introduction of recombinant human erythropoietin, the [...]

#SCM16: Vadadustat and Anemia

April 29, 2016 // 0 Comments

Dr. Volker Haase (VH), from Vanderbilt University in Nashville, Tennessee, discusses his abstract for the National Kidney Foundation’s 2016 Spring Clinical Meetings [...]

NephMadness 2016: Dr. Coyne tells his role in the Normalization of Hemoglobin story

April 3, 2016 // 3 Comments

Normalization of hemoglobin has been a dominant force in this NephMadness and is poised for greatness in the Filtered Four. One of the key players in the story is Daniel [...]

IRON or No IRON: Does One Size Fit All?

February 25, 2016 // 1 Comment

Anemia is a common complication of advanced chronic kidney disease (CKD) and end-stage renal disease (ESRD), and anemia management is a critical element of care for these [...]

Novel Options in Iron Supplementation

February 1, 2016 // 1 Comment

CKD and anemia go together like Donald Trump and hairspray. And as with every lab abnormality, nephrologists want to fix the anemia despite a thin trail of evidence [...]

Which ESA Is Safer in Chronic Kidney Disease Patients?

February 19, 2015 // 0 Comments

Epoetin alfa (EPO) and darbepoetin alfa (DPO) are two erythropoiesis-stimulating agents (ESAs) commonly used for treatment of anemia in chronic kidney disease (CKD). DPO has [...]

Emerging Role of Biosimilar Epoetins

January 26, 2015 // 0 Comments

Recently published in AJKD is a timely perspective by Fishbane et al of the emerging role of biosimilar erythropoiesis-stimulating agents (ESAs) in US nephrology practice. [...]

Before and After TREAT

September 8, 2014 // 0 Comments

In a recent article published in AJKD, Thamer at al did a retrospective observational investigation of the ESA prescribing patters before and after publication of the TREAT [...]

SCM14: Let’s Bind With Velphoro

April 24, 2014 // 1 Comment

Dr. Stuart Sprague (SS) from the North Shore University Health System and University of Chicago Pritzker School of Medicine discusses his abstract for the National Kidney [...]